Literature DB >> 10965883

Fibroblast growth factor-2 inhibits the maturation of pro-insulin-like growth factor-II (Pro-IGF-II) and the expression of insulin-like growth factor binding protein-2 (IGFBP-2) in the human adrenocortical tumor cell line NCI-H295R.

N Boulle1, C Gicquel, A Logié, R Christol, J J Feige, Y Le Bouc.   

Abstract

The IGF system is thought to play a major role in adrenocortical tumorigenesis. In this study, we used the NCI H295R cell line as a model to investigate the effects of fibroblast growth factor-2 (FGF-2), a potent mitogen for normal adrenal cells, on the proliferation and on the expression of the IGF system in cultured adrenocortical tumor cells. Three immunoreactive FGF-2 isoforms of molecular masses 18, 22, and 24 kDa were detected in H295R cell extracts. Recombinant human FGF-2 stimulated the proliferation of adrenocortical tumor cells in a dose- and time-dependent manner, with a maximal effect at a concentration of about 1 ng/ml. Treatment of H295R cells with 10 ng/ml FGF-2 for 7 days had no significant effect on IGF-II messenger RNA levels. However, a marked increase in levels of intracellular IGF-II protein was detected by immunoblotting. In contrast, FGF-2 induced a marked decrease in the amount of IGF-II protein secreted, with the disappearance of mature IGF-II and secretion of higher molecular forms of the growth factor, suggesting modifications of IGF-II processing. Cell cultures in the presence of brefeldin A (1 microg/ml), a specific inhibitor of protein secretion, suggested that FGF-2 did not increase IGF-II synthesis but instead inhibited the secretion of pro-IGF-II from H295R cells, thereby impairing the final steps of IGF-II processing to the mature 7.5-kDa peptide. At the same concentrations, FGF-2 also decreased both IGFBP-2 messenger RNA and secreted protein, which might increase IGF-II bioavailability. No proteolysis of IGFBP-2 was detected in FGF-2-conditioned medium. Altogether, these results indicate that FGF-2 is mitogenic for NCI H295R tumor cells and regulates the expression of both IGF-II and IGFBP-2 in this tumor model. Moreover, this study shows a novel effect of FGF-2, by which this growth factor modulates the processing of pro-IGF-II.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10965883     DOI: 10.1210/endo.141.9.7632

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

Review 1.  Review paper: origin and molecular pathology of adrenocortical neoplasms.

Authors:  M Bielinska; H Parviainen; S Kiiveri; M Heikinheimo; D B Wilson
Journal:  Vet Pathol       Date:  2009-03       Impact factor: 2.221

Review 2.  How the new tools to analyze the human genome are opening new perspectives: the use of gene expression in investigations of the adrenal cortex.

Authors:  C A Stratakis; A Horvath
Journal:  Ann Endocrinol (Paris)       Date:  2008-04-18       Impact factor: 2.478

Review 3.  Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms.

Authors:  Ozgur Mete; Sylvia L Asa; Thomas J Giordano; Mauro Papotti; Hironobu Sasano; Marco Volante
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

4.  Subcellular localization of fibroblast growth factor receptor type 2 and correlation with CTNNB1 genotype in adrenocortical carcinoma.

Authors:  Matthias Haase; Anne Thiel; Ute I Scholl; Hany Ashmawy; Matthias Schott; Margret Ehlers
Journal:  BMC Res Notes       Date:  2020-06-10

Review 5.  Insulin-Like Growth Factor 2 As a Possible Neuroprotective Agent and Memory Enhancer-Its Comparative Expression, Processing and Signaling in Mammalian CNS.

Authors:  Alexander Beletskiy; Ekaterina Chesnokova; Natalia Bal
Journal:  Int J Mol Sci       Date:  2021-02-12       Impact factor: 5.923

Review 6.  FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma.

Authors:  Mariangela Tamburello; Barbara Altieri; Iuliu Sbiera; Sandra Sigala; Alfredo Berruti; Martin Fassnacht; Silviu Sbiera
Journal:  Endocrine       Date:  2022-05-18       Impact factor: 3.925

7.  Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications.

Authors:  Iuliu Sbiera; Stefan Kircher; Barbara Altieri; Kerstin Lenz; Constanze Hantel; Martin Fassnacht; Silviu Sbiera; Matthias Kroiss
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-09       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.